MLH1 and hereditary cancer: As the adoption of universal screening by pathology centers becomes more widespread and may not be uniform in its ability to prescreen cases for likely sporadic cases using accompanying BRAF IHC or MLH1 hypermethylation analysis, new modes of clinical triage that include brief medical history review and initiation of ancillary tests prior to appointment are being implemented to identify cases that may not require additional hereditary cancer assessment.